Pro-Dex (PDEX) Competitors

Pro-Dex (NASDAQ:PDEX) and Bioventus (NYSE:BVS) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, media sentiment, risk, dividends, profitability, analyst recommendations, institutional ownership and valuation.

Which has more volatility & risk, PDEX or BVS?

Pro-Dex has a beta of 0.19, indicating that its share price is 81% less volatile than the S&P 500. Comparatively, Bioventus has a beta of 0.83, indicating that its share price is 17% less volatile than the S&P 500.

Which has higher earnings & valuation, PDEX or BVS?

Pro-Dex has higher earnings, but lower revenue than Bioventus.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pro-Dex	$64.12M	2.23	$2.13M	$2.80	15.69
Bioventus	$564.14M	1.07	-$156.23M	N/A	N/A

Do insiders & institutionals hold more shares of PDEX or BVS?

15.3% of Pro-Dex shares are owned by institutional investors. Comparatively, 62.9% of Bioventus shares are owned by institutional investors. 47.5% of Pro-Dex shares are owned by company insiders. Comparatively, 33.0% of Bioventus shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Does the media refer more to PDEX or BVS?

In the previous week, Pro-Dex and Pro-Dex both had 3 articles in the media. Bioventus' average media sentiment score of 0.74 beat Pro-Dex's score of -0.07 indicating that Bioventus is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pro-Dex	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Bioventus	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts rate PDEX or BVS?

Pro-Dex currently has a consensus target price of $56.00, indicating a potential upside of 27.50%. Bioventus has a consensus target price of $13.75, indicating a potential upside of 87.84%. Given Bioventus' higher probable upside, analysts clearly believe Bioventus is more favorable than Pro-Dex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pro-Dex	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Bioventus	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

Is PDEX or BVS more profitable?

Pro-Dex has a net margin of 14.61% compared to Bioventus' net margin of -7.11%. Pro-Dex's return on equity of 29.08% beat Bioventus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pro-Dex	14.61%	29.08%	16.19%
Bioventus	-7.11%	15.61%	4.01%

Summary

Pro-Dex beats Bioventus on 8 of the 14 factors compared between the two stocks.